Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.

[1]  V. Woo,et al.  Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years , 2014, Diabetes, obesity & metabolism.

[2]  C. Kovacs,et al.  Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial , 2014, Diabetes, obesity & metabolism.

[3]  J. Rosenstock,et al.  Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia , 2013, Diabetes, obesity & metabolism.

[4]  E. Ferrannini,et al.  Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin , 2013, Diabetes Care.

[5]  M. Roden,et al.  Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. , 2013, The lancet. Diabetes & endocrinology.

[6]  H. Häring,et al.  Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes , 2013, Diabetes Care.

[7]  G. Charpentier,et al.  Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial , 2013, International journal of clinical practice.

[8]  I. Tikkanen,et al.  Empagliflozin Improves Blood Pressure in Patients with Type 2 Diabetes (T2DM) and Hypertension , 2013 .

[9]  R. DeFronzo,et al.  Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes , 2013, Diabetes Care.

[10]  Lawrence A Leiter,et al.  Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial , 2013, The Lancet.

[11]  A. Januszewicz,et al.  Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial , 2013, Diabetologia.

[12]  D. Matthews,et al.  Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes , 2013, Annals of Internal Medicine.

[13]  J. Rosenstock,et al.  Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea , 2013, Diabetes Care.

[14]  E. Ferrannini,et al.  A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[15]  D. de Zeeuw,et al.  Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[16]  A. Kiyosue,et al.  Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double‐blind, placebo‐controlled trial , 2013, Diabetes, obesity & metabolism.

[17]  E. Ferrannini,et al.  Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose‐finding study , 2013, Diabetes, obesity & metabolism.

[18]  E. Ferrannini,et al.  Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. , 2013, Journal of diabetes and its complications.

[19]  R. Guthrie.  Sodium-Glucose Co-Transporter 2 Inhibitors and the Potential for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus , 2013, Postgraduate medicine.

[20]  B. Bode,et al.  Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized Trial , 2013, Hospital practice.

[21]  G. Bakris,et al.  Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease , 2013, Diabetes, obesity & metabolism.

[22]  T. Mansfield,et al.  Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial , 2013, BMC Medicine.

[23]  K. Kim,et al.  Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise , 2013, Diabetes, obesity & metabolism.

[24]  N. Iqbal,et al.  Dapagliflozin monotherapy in drug‐naïve patients with diabetes: a randomized‐controlled trial of low‐dose range , 2012, Diabetes, obesity & metabolism.

[25]  J. Rosenstock,et al.  Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy , 2012, Diabetes Care.

[26]  R. Henry,et al.  Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial , 2012, International journal of clinical practice.

[27]  J. Kullberg,et al.  Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. , 2012, The Journal of clinical endocrinology and metabolism.

[28]  B. Cheung,et al.  Diabetes and Hypertension: Is There a Common Metabolic Pathway? , 2012, Current Atherosclerosis Reports.

[29]  R. S. Porter,et al.  The Merck Manual Home Health Handbook , 2011 .

[30]  K. Yoon,et al.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial , 2011, Diabetes, obesity & metabolism.

[31]  S. Del Prato,et al.  Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin , 2011, Diabetes Care.

[32]  D. Loo,et al.  Biology of human sodium glucose transporters. , 2011, Physiological reviews.

[33]  C. Bailey,et al.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.

[34]  E. Ferrannini,et al.  Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise , 2010, Diabetes Care.

[35]  J. Gerich.  Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[36]  P. Norwood,et al.  A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers , 2009, Diabetes Care.

[37]  Enrique Morales,et al.  Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes , 2008, Diabetes Care.

[38]  Kdoqi.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[40]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[41]  M. Hediger,et al.  Molecular physiology of sodium-glucose cotransporters. , 1994, Physiological reviews.